Managers / Q1 2025 · view latest →
Vantage Consulting Group Inc
CIK 0001843547 · 3500 PACIFIC AVE, VIRGINIA BEACH, VA, 23451 · 757-491-1200
Summary
Vantage Consulting Group Inc reported $5M in U.S.-listed holdings across 4 positions for Q1 2025.
The portfolio is heavily concentrated: CBUS alone accounts for 42.6% of reported value.
Compared with Q4 2024, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 76.1% · $4M
- Other · 23.9% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PTBPotbelly Corporation | SOLD OUT | −164.9K | 0 | −$2M | $0 |
| BWBabcock & Wilcox Enterprises Inc. | HELD | +0 | 2.42M | −$2M | $2M |
| CBUSCibus, Inc. | HELD | +0 | 1.14M | −$1M | $2M |
| ADC Therapeutics SA | HELD | +0 | 850.7K | −$493,428 | $1M |
| Fibrogen, Inc | HELD | +0 | 195.7K | −$42,977 | $60,650 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CBUSCibus, Inc.history → | COM | 42.58% | $2M | 1.14M |
| 2 | BWBabcock & Wilcox Enterprises Inc.history → | COM | 32.34% | $2M | 2.42M |
| 3 | ADC Therapeutics SA | COM | 23.88% | $1M | 850.7K |
| 4 | Fibrogen, Inc | COM | 1.21% | $60,650 | 195.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2025 | $20M | 3 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $11M | 3 | Nov 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $6M | 3 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $5M | 4 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $10M | 5 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $11M | 4 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $135M | 191 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $157M | 212 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $149M | 208 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $149M | 200 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $174M | 216 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $176M | 231 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $169M | 212 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $171M | 213 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $178M | 213 | Aug 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $256M | 215 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $372M | 231 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $467M | 206 | Nov 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $575M | 211 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $498M | 99 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.2B | 1,884 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.